Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scipione

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Microbiology Spectrum|November 29, 2023
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Microbiology Spectrum|November 29, 2023
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Pageof 4